Moderna's mFLUSIVA Flu Vaccine Receives U.S. FDA Approval for Adults 50 and Older

The U.S. Food and Drug Administration (FDA) has approved Moderna's mFLUSIVA (mRNA-1010), a new mRNA-based vaccine for seasonal influenza, for use in adults aged 50 years and older. This marks Moderna's fourth approved product in the U.S. and the first mRNA flu vaccine, offering a new option for older adults.